中国药物警戒 ›› 2024, Vol. 21 ›› Issue (10): 1143-1147.
DOI: 10.19803/j.1672-8629.20240064

• 安全与合理用药 • 上一篇    下一篇

97例注射用尤瑞克林不良反应分析

陈春燕1,2, 汤颖婕3, 赵海霞1,2, 潘慧敏1,2, 朱青梅1,2,*   

  1. 1新疆医科大学第一附属医院药学部,新疆 乌鲁木齐 830054;
    2新疆药物临床研究重点实验室,新疆 乌鲁木齐 830000;
    3新疆医科大学药学院,新疆 乌鲁木齐 830000
  • 收稿日期:2024-01-25 出版日期:2024-10-15 发布日期:2024-10-14
  • 通讯作者: *朱青梅,女,硕士,主管药师,临床药学。E-mail：zhuqingmei111@126.com
  • 作者简介:陈春燕,女,硕士,主管药师,临床药学。
  • 基金资助:
    新疆维吾尔自治区药学会科研基金项目（YXH202115、YXH202216）; 中关村精准医学基金会-药学科研专项（ZGC-YXKY-65）

Ninety-seven cases of adverse drug reaction caused by urinary kininogenase for injection

CHEN Chunyan1,2, TANG Yingjie3, ZHAO Haixia1,2, PAN Huimin1,2, ZHU Qingmei1,2,*   

  1. 1Department of Clinical Pharmacy, The First Affiliated Hospital of Xinjiang Medical University, Urumqi Xinjiang 830054, China;
    2Xinjiang Key Laboratory of Clinical Drug Research, Urumqi Xinjiang 830000, China;
    3School of Pharmacy, Xinjiang Medical University, Urumqi Xinjiang 830000, China
  • Received:2024-01-25 Online:2024-10-15 Published:2024-10-14

PDF (PC)

86

摘要： 目的 研究注射用尤瑞克林药品不良反应（adverse drug reaction, ADR）发生规律与特点,为临床安全用药提供参考。方法 收集本院2020年1月1日至2023年12月31日监测上报的注射用尤瑞克林ADR报告,对患者的基本信息、ADR类型、累及系统-器官、临床表现、ADR转归及处理措施、用药合理性等进行分析。结果 97例注射用尤瑞克林ADR中,男性患者居多为64例（65.98%）;用药天数最短为1 d,最长13 d;单用尤瑞克林的患者12例,联合使用降压药物或其他脑梗死药物的患者85例;80例（82.47%）发生于首次用药24 h内;ADR主要累及心血管系统、神经/精神和消化系统,临床表现为血压下降、出汗、恶心、呕吐等,经停药或对症处理后大部分好转;新的ADR 29例次,严重ADR 2例次,新的严重的ADR 1例次。不合理用药14例。结论 临床使用注射用尤瑞克林时应重视相关ADR监测,确保安全合理用药。

关键词: urinary kininogenase, injection, adverse drug reaction, safety, cardiovascular, neurological, digestive systems

Abstract: Objective To analyze the characteristics and patterns of adverse drug reaction (ADR) caused by urinary kininogenase for injection so as to provide reference for rational use of this drug. Methods A total of 97 cases of ADR related to urinary kininogenase for injection reported between 2020 and 2023 were collected. The basic data, types of ADR, clinical manifestations, involved systems-organs, and rationality of medication were analyzed. Results Among the 97 cases of ADR related to urinary kininogenase for injection, male patients outnumbered female ones (64 cases, 65.98%). The course of treatment ranged from one day to thirteen days. There were 85 patients treated with antihypertensive drugs or other cerebral infarction drugs. Most of these ADR occurred within 24 hours of the first use of drugs, and involved the cardiovascular, neurological/psychiatric, and digestive systems, with such clinical manifestations as decreased blood pressure, sweating, nausea and vomiting, most of them improved after drug withdrawal or symptomatic treatment. There were 29 cases of new ADR, 2 cases of severe ADR, and 1 case of new and severe ADR. In total, there were 14 cases of irrational medication. Conclusion There is the need to improve the ADR monitoring of urinany kininogenase for injection to ensure the safety of medications.

Key words: urinary kininogenase, injection, adverse drug reaction, safety, cardiovascular, neurological, digestive systems

中图分类号: